Inside the Drug Tavneos Scandal: How Clinical Trial Data Was "Engineered" for FDA Approval

The pharmaceutical world is currently reeling from the news that the FDA’s Center for Drug Evaluation and Research (CDER) has proposed a full market withdrawal of Tavneos (avacopan). The drug manufacturer, Amgen, is embroiled with the FDA in the dispute about the withdrawal of Tavneos.

•  FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug
• The FDA Cracks Down on Tavneos
• Amgen Updates Tavneos Label While US FDA Weighs Withdrawal Proposal

While drug recalls for safety are not uncommon, this case is unique: the FDA alleges that the drug’s original developer, ChemoCentryx, engaged in deliberate data manipulation to secure its 2021 approval. Tavneos was approved in 2021 to treat a rare autoimmune disease called ANCA-associated vasculitis. Amgen scooped it up the following year in its $4 billion acquisition of ChemoCentryx.

The "how" behind this manipulation is a masterclass in statistical engineering and the violation of clinical trial integrity. Based on the internal "Walton Report" and subsequent investigations, here is exactly how the results of the pivotal ADVOCATE trial were doctored.

The 15-Day Manipulation Window

The integrity of a clinical trial rests on the "blind"—the rule that researchers don't know who is getting the drug and who is getting the placebo until the results are finalized. In a standard clinical trial, once the database is locked, the assignments are unblinded, and the statistical analysis begins. Any changes after this point are typically forbidden unless they involve the correction of clear, documented clerical errors identified through blinded quality control.

In the ADVOCATE trial, the data was officially locked on November 5, 2019 and sponsor (ChemoCentryx at that time) performed two step processes for the database lock (i.e., the initial lock and the database relock – final lock). The misconduct to manipulate the data occurred during the initial database lock and the database relock. The timeline of the alleged misconduct is listed below.

An initial analysis conducted immediately after this lock showed a devastating result: Tavneos failed to meet its primary endpoint of superiority for sustained remission at 52 weeks. According to the FDA, this was a "not statistically significant" result that should have ended the drug's path to approval. The sponsor then ‘manipulated’ the data following the steps below:

Step 1: Breaking the Blind

On November 6, 2019, two high-ranking officials—Director of Biostatistics Mr. Yue and Chief Medical Officer Dr. Bekker—were granted access to the unblinded data. Instead of accepting the failed result, the FDA alleges these individuals specifically hunted for patient cases that could be altered to flip the p-value into the significant range.

Step 2: The "Hypothetical Dataset"

Before making any official changes, Yue and Bekker reportedly created a "hypothetical dataset". This was essentially a simulation to see exactly how many patients needed their status changed from "non-responder" to "responder" to achieve statistical superiority. They identified nine specific subjects for "readjudication"—six in the Tavneos arm and three in the control arm.

Step 3: Targeted Reclassification

The manipulation targeted patients where protocol rules regarding "missing data" or "glucocorticoid use" could be creatively reinterpreted.

In total, five of the six targeted Tavneos patients were successfully changed to "responders". Crucially, not a single patient in the control arm was reclassified. This asymmetric adjustment pushed the p-value to p < 0.001, creating the illusion of a highly successful drug.

Step 4: The Omission of Truth

When the New Drug Application (NDA) was submitted to the FDA in 2020, ChemoCentryx included only the second, manipulated analysis. They failed to disclose that an original, failing analysis had ever existed or that unblinded personnel had "corrected" the data after the fact. This is why the FDA now cites "untrue statements of material fact" as a primary reason for withdrawal.

The Human Cost

This wasn't just a victimless statistical crime. By manufacturing proof of effectiveness, the developers downplayed the drug's severe risks. Since its approval, the FDA has flagged 76 cases of drug-induced liver injury (DILI) causally linked to Tavneos, including 8 deaths. Some patients developed Vanishing Bile Duct Syndrome (VBDS), a rare condition that progressively destroys the liver’s bile ducts.

Current Status

Amgen, which acquired ChemoCentryx for $3.7 billion in 2022, maintains that it is not aware of any issues with the underlying patient data and stands by the drug's safety profile. However, the FDA has issued a Notice of Opportunity for a Hearing (NOOH), a formal step toward stripping the drug of its marketing rights.

Until a final ruling is made, Tavneos remains on the market, leaving thousands of patients and doctors in a difficult position: weighing a "breakthrough" that may have been a statistical mirage against the risk of fatal liver failure.

Conclusion 

The basic principles in the randomized, double blinded clinical trial prohibit the data changes after the study is unblinded. The study unblinding must occur after the database is locked. 

Two step database lock process is flawed and should be abandoned.  

Any data review and endpoint adjudication should be conducted in the blinded fashion and must be completed before the database lock/study unblinding. 

Any violation of these principles will cause the suspicion of the data manipulation and the data integrity is compromised. 

References:

• Amgen's Tavneos faces withdrawal after FDA probe flags data tampering
• CDER proposes to withdraw approval of TAVNEOS - FDA, accessed April 28, 2026
• FDA proposes to withdraw Amgen's drug for rare autoimmune diseases over effectiveness, accessed April 28, 2026
• Advocating for Patients with Vasculitis: A Steroid-Sparing Regimen with Avacopan - NephJC
• FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study - Oxford Academic
• Amgen's Tavneos faces withdrawal after FDA probe flags data tampering
• An Important Update Regarding TAVNEOS® (avacopan) - Amgen
• FDA turns up heat on Amgen, proposing to rescind approval of Tavneos - Fierce Pharma 2026,
• Letter NOOH Taveneos (avacopan) - FDA
• Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan - PMC
• Letter NOOH Taveneos (avacopan) - FDA
• United States D istrict Court Northern District of Ca
• FDA Warns of Serious Liver Injury Risks From Vasculitis Drug Tavneos
• FDA Issues Safety Alert on Amgen Vasculitis Drug - Global Genes
• FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries

The Statistical Magic Trick: How Trials Share Results While Staying Blind

 

In the world of clinical research, "breaking the blind" is typically a cardinal sin. Yet, high-stakes Phase 3 trials like ORIGIN 3 (atacicept), PROTECT (sparsentan), and ATTRIBUTE-CM (acoramidis) have all successfully navigated the complex path of publishing interim results in the New England Journal of Medicine while keeping their long-term studies scientifically intact.

• Lafayette et al (2026) A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
• Perkovic et al (2026) Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
• Gillmore, et al (2024)Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy and its attached protocol and statistical analysis plan "

How do they pull off this statistical magic trick? It comes down to a rigorous architectural separation of data and people including statistical analysis team. Here is a look at the techniques used to maintain the "blind" during interim disclosures.

1. The "Firewall" Strategy: Independent Reporting Teams

The most critical technique used across all three studies is the creation of a "Firewall."

While a trial is ongoing, the people running the study (Sponsor clinical teams, investigators at hospitals, and the patients) must remain blinded. To perform an interim analysis, the Sponsor appoints an Independent Reporting Team (IRT) or an Independent Statistical Center.

• How it works: This group has no contact with the study sites. They receive the raw "unblinded" data, perform the calculations for the primary endpoint (like the 36-week proteinuria reduction in PROTECT or ORIGIN 3), and prepare the manuscript for publication.
• The Result: The people actually treating the patients remain in the dark, ensuring their medical decisions aren't influenced by knowing who is on the "winning" drug.

2. Safeguarding Against "Functional Unblinding"

In some trials, the drug’s effect is so obvious it could accidentally reveal the treatment.

• In ORIGIN 3: Atacicept significantly lowers serum IgA and IgG levels. If a doctor saw these lab results, they would immediately know the patient was on the active drug. To prevent this, these specific lab values are suppressed. The results are sent to the Independent Reporting Team but are hidden from the investigators and the Sponsor’s site monitors.
• In PROTECT: This study compared two active drugs (sparsentan vs. irbesartan). To ensure the difference in pill appearance didn't tip anyone off, they used a Double-Dummy design. Every patient took two sets of pills—one active and one placebo—so the physical routine remained identical for everyone.

3. Aggregate vs. Individual Disclosure

A common misconception is that "publishing the results" means everyone knows who got what. In reality, the NEJM publications for these trials only disclose aggregate data (group averages), not the individual patient level data.

• In ATTRIBUTE-CM: When the Part A results (12-month 6-minute walk distance) were disclosed, the public learned how the group performed. However, the individual treatment assignments for each patient remained locked in the secure database.
• The Benefit: Even if an investigator reads the NEJM article and sees that acoramidis is effective, they still do not know if the specific patient sitting in their office is receiving acoramidis or the placebo.

4. Prespecified Alpha Spending and "The Gatekeeper"

To maintain the statistical integrity of the final results (like the 104-week kidney function in ORIGIN 3 or the 30-month clinical outcomes in ATTRIBUTE-CM), the Statistical Analysis Plan (SAP) dictates exactly how much "statistical credit" is used during the interim look.

• The Independent Data Monitoring Committee (iDMC) acts as the gatekeeper. They review the unblinded data behind closed doors and only allow the trial to proceed if the interim disclosure doesn't compromise the "power" of the final analysis.

Why go through all this trouble?

The goal is Accelerated Approval. By using these techniques, sponsors can show the FDA (and the medical community) that a drug works on a "surrogate marker" (like proteinuria) at an interim stage. This allows life-saving drugs to reach patients years earlier, while the "blinded" portion of the trial continues to gather the long-term data needed for full, traditional approval.

By combining physical dummies, suppressed lab data, and strict "firewalls" between statistical teams, researchers prove that you can indeed share the news of a trial's success without ruining the science that supports it.

Some Extra Words on ATTRIBUTE-CM Study

ATTRIBUTE-CM study is a phase 3, double-blind trial, 632 patients with transthyretin amyloid cardiomyopathy were randomly assigned in a 2:1 ratio to receive acoramidis hydrochloride at a dose of 800 mg twice daily or matching placebo for 30 months. The study contained two parts: Part A with primary endpoint of change from baseline to Month 12 of treatment in distance walked during the 6MWT, Part B with primary endpoint of a hierarchical combination of All-Cause mortality and CV-related hospitalization over a 30month period.

There were two readouts for the study and the Part A readouts were based on an interim analyses by the independent DMC. 

In December 2021, BridgeBio Pharma experienced a major setback when its Phase 3 ATTRibute-CM trial for acoramidis (a treatment for transthyretin amyloid cardiomyopathy - ATTR-CM) failed to meet its primary endpoint of improving the 6-minute walk distance (6MWD) at Month 12 (Part A primary efficacy endpoint). In the initial 12-month data, patients taking acoramidis did not show a statistically significant improvement in their 6MWD compared to those on a placebo.

Despite the failure of the 6MWD endpoint at 12 months, the study continued because the independent data monitoring committee noted encouraging trends in other areas. By July 2023, BridgeBio reported positive top-line results from the full study (Month 30), where acoramidis demonstrated a highly statistically significant improvement in a hierarchical analysis that included mortality, hospitalization, and 6MWD (Part B primary efficacy endpoint). 

Following the successful long-term data (Part B), which showed a 25% reduction in all-cause mortality and 50% reduction in cardiovascular hospitalization frequency (known as Attruby), the drug was approved by the FDA, with 3,751 prescriptions filled as of August 2025.

The study included an embedded Part A readouts that required the unblinding for interim analysis. The sponsor specified the following for maintaining the blinding for the overall study while the Part A results were analyzed and disclosed.